Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines
Citations Over TimeTop 11% of 2008 papers
Abstract
A series of beta-aminoamides bearing triazolopiperazines have been discovered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive structure-activity relationship (SAR) studies around the triazolopiperazine moiety. Among these, compound 34b with excellent in vitro potency (IC50 = 4.3 nM) against DPP-4, high selectivity over other enzymes, and good pharmacokinetic profiles exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice. On the basis of these properties, compound 34b has been profiled in detail. Further refinement of the triazolopiperazines resulted in the discovery of a series of extremely potent compounds with subnanomolar activity against DPP-4 (42b- 49b), that is, 4-fluorobenzyl-substituted compound 46b, which is notable for its superior potency (IC50 = 0.18 nM). X-ray crystal structure determination of compounds 34b and 46b in complex with DPP-4 enzyme revealed that (R)-stereochemistry at the 8-position of triazolopiperazines is strongly preferred over (S) with respect to DPP-4 inhibition.
Related Papers
- → Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries(2011)72 cited
- → Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties(1996)26 cited
- → Identification of Bile Canalicular Cell Surface Antigen HAM.4 as Dipeptidyl Peptidase IV (DPPIV) and Characterization of Its Role in Hepatic Regeneration After Partial Hepatectomy in Rats(1998)4 cited
- → Cardiovascular studies in mouse, rat, dog and monkey show no clinically relevant effects of the DPPIV inhibitor saxagliptin(2015)1 cited
- → CD26/dipeptidyl peptidase IV (DPPIV, DAPIV) is a useful molecular marker for thyroid carcinomas(2013)